Paula Villatoro, researcher at IR Sant Pau and member of the Strokemics group, is co-principal investigator of CADASIMUS, a collaborative project recently awarded seed funding by the RICORS-ICTUS network.
The project aims to explore a repurposed drug as a potential treatment for CADASIL, a rare genetic small vessel disease, using patient-derived cell models and proteomic analysis. IR Sant Pau contributes through the CADAGENIA registry and collaboration with the CADASIL Spain Association.
The initiative highlights the group’s commitment to rare disease research and precision medicine.
Read the full article here.
